Research and Development

The key point of Deltha Pharma is its Research & Development department, which is made up of various professionals who are constantly on the lookout for new raw materials and the related tests and clinical results. Every year based on research and the needs of the population, a large number of new and innovative products are formulated. After this, samples are then taken for analysis and testing. It is only after these tests are completed that industrial production of the new supplements begins.

The raw materials used are almost solely exclusive patents and carrier substances to improve the bioavailability of the active ingredients.

In 2020, Deltha Pharma signed an agreement with the Università Cattolica del Sacro Cuore in Rome and has a worldwide exclusive license for the patent of a bacterial consortium formulated by professors at the Policlinico A. Gemelli in Rome and marketed under the brand name MASUROTA.


Training and Education Seminar

The product list is presented to the medical profession by a network of highly competent and experienced medical representatives throughout the country.

All the communication proposed to doctors is validated by a committee of consultants and university professors who not only verify the correctness and clarity of the presentation, but also support the marketing of the products through clinical studies carried out at the most accredited public and private health facilities.

Medical Congress

Deltha Pharma participates in a large number of medical congresses in the therapeutic areas of interest or actively promotes the organization of congresses or webinars in the thematic areas of interest.

It also promotes research and the conduct of clinical and pre-clinical studies both in collaboration with Hospital-University Institutes and on the territory, in accordance with the latest guidelines of the Ministry of Health on clinical work concerning the therapeutic and preventive value of food supplements.

With this in mind, two studies on the Urological-Urogynecological line saw the start in 2018-2019, aimed at assessing the contribution of Delthamannosio in the treatment and prevention of recurrent cystitis and the role of Delthaprost in the variation of lower urinary tract symptoms (LUTS).

In 2021, a double-blind study started at the Policlinico A.Gemelli in Rome on the efficacy of MASUROTA in patients with intestinal dysbiosis from antibiotics.

Deltha Pharma is also an ideal environment for growth and training, hosting internships in the scientific and technological-administrative fields for graduates.